Testing three drugs together for lung cancer that spread to the brain
Original title: A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage test in people, and the answers are not in yet.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests three cancer drugs given together after lung cancer spreads to the brain.
Who this trial is for. This trial is for people with non-small cell lung cancer that has spread to the brain and has not been treated yet. It tests datopotamab deruxtecan, carboplatin, and pembrolizumab given every three weeks for four cycles, then two of the drugs kept going.
Where it stands. The trial has not reported results. The study team is watching whether the cancer grows and how well people handle the drugs. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: Someone with this kind of lung cancer in the brain might fit this study. It is fair to ask your care team about it. They can help you decide if it makes sense for you.
What it doesn't mean: This does not mean the drug mix works. A trial is a test, not a proven treatment. Joining one is not a promise of help. It is not a cure, and it is not care you can get from your own doctor today.
Source: ClinicalTrials.gov, August 14, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.